|Bid||22.15 x 0|
|Ask||22.30 x 0|
|Day's Range||21.83 - 22.40|
|52 Week Range||7.90 - 24.10|
|Beta (3Y Monthly)||-0.05|
|PE Ratio (TTM)||83.15|
|Earnings Date||Aug 30, 2016 - Sep 3, 2016|
|Forward Dividend & Yield||0.02 (0.09%)|
|1y Target Est||32.70|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in accordance with 21 CFR.
The direct benefit for Clinuvel Pharmaceuticals Limited (ASX:CUV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
Understanding Clinuvel Pharmaceuticals Limited’s (ASX:CUV) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
Clinuvel Pharmaceuticals Limited (ASX:CUV) is currently trading at a trailing P/E of 78.9x, which is higher than the industry average of 28x. While CUV might seem like a stock toRead More...